Search
Showing results for "lung disease preterm"
Cystic fibrosis is an inherited condition that results in chronic lung disease. In recent years, a new type of medication called CFTR modulators has become available.
In this study, we aimed to uncover the molecular mechanisms contributing to altered lung structure and function.
The MELODY Study is a Phase 3 randomized, double-blind, placebo-controlled, single-dose study to determine if MEDI8897 will prevent medically attended Respiratory Syncytial Virus (RSV) -confirmed Lower Respiratory Tract Infection (LRTI) in healthy infants entering their first RSV season.
Protease elastase exocytosis by airway neutrophils occurs in all cystic fibrosis children, and its cellular measure correlates with early lung damage
Conditionally reprogrammed primary airway epithelial cells maintain morphology, lineage and disease specific functional characteristics The study of
Early disease surveillance in young children with cystic fibrosis: A qualitative analysis of parent experiences Sensitive measures of early lung
Macrophages are the major resident immune cells in human airways coordinating responses to infection and injury. In cystic fibrosis, neutrophils are recruited to the airways shortly after birth, and actively exocytose damaging enzymes prior to chronic infection, suggesting a potential defect in macrophage immunomodulatory function.
This document updates the 2005 European Respiratory Society (ERS) and American Thoracic Society (ATS) technical standard for the measurement of lung volumes. The 2005 document integrated the recommendations of an ATS/ERS task force with those from an earlier National Heart, Lung, and Blood Institute workshop that led to the publication of background papers between 1995 and 1999 and a consensus workshop report with more in-depth descriptions and discussion.
Mycobacteroides abscessus (MABS) is within the non-tuberculous mycobacteria family. It inhabits soil and water, exhibits multi-antibiotic resistance and causes opportunistic lung infections, which may progress to symptomatic MABS-pulmonary disease (MABS-PD) associated with substantial morbidity, increased healthcare utilisation, impaired quality of life and increased mortality.
All alterations to lung mechanics following in utero arsenic exposure were recovered by adulthood.